Management of Chronic Lymphocytic Leukemia

OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years in recurrent, fully resected osteosarcoma and lung metastases.

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options for a patient with metastatic non–small cell lung cancer (NSCLC), with participants.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

LOAd703, an oncolytic adenovirus with transgenes for 4-1BBL and TMZ-CD40L, has received FDA fast track designation for pancreatic cancer treatment.

FoundationOne CDx is now FDA-approved as the first companion diagnostic for tovorafenib, enabling targeted treatment for relapsed/refractory pediatric low-grade glioma with BRAF mutations or rearrangements.